What is it about?
We review tips for screening methods of Transthyretin Cardiac Amyloidosis (ATTR-CM) in clinical practice and new drug therapies for ATTR-CM.
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
ATTR‐CM demonstrates infiltrative cardiomyopathy caused by extracellular deposition of insoluble transthyretin amyloid fibrils in the myocardium. ATTR-CM is progressive and life‐threatening if left untreated, and thus, early diagnosis is critical. However, the development of a proper strategy to reach the correct diagnosis and treatment of ATTR-CM has been long overdue.
Perspectives
We will be able to identify ATTR-CM early and effectively manage patients with ATTR-CM using new drug therapies.
Dr. Hiroyuki Yamamoto
Tokyo Ika Daigaku
Read the Original
This page is a summary of: Transthyretin cardiac amyloidosis: an update on diagnosis and treatment, ESC Heart Failure, September 2019, Wiley,
DOI: 10.1002/ehf2.12518.
You can read the full text:
Contributors
The following have contributed to this page
